Neoplasms

All Conditions

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Thyroid Neoplasms

Thyroid Diseases

Carcinoma, Medullary

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Endocrine System Diseases

Endocrine Gland Neoplasms

Head and Neck Neoplasms

Carcinoma, Neuroendocrine

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Adenocarcinoma

Neoplasms, Nerve Tissue

Thyroid Cancer, Medullary

Neuroendocrine Tumor

Neuroepithelioma

All Drugs and Chemicals

Anti-Dyskinesia Agents

Bone Density Conservation Agents

Vasodilator Agents

Cardiotonic Agents

Antibodies

Levodopa

Immunoglobulins

Calcitonin

Salmon calcitonin

Calcitonin Gene-Related Peptide

Katacalcin

Dihydroxyphenylalanine

Dopamine

Dopamine Agents

Neurotransmitter Agents

Antiparkinson Agents

PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA

18F-L-DOPA PET

Badia-Ourkia HELAL, MD

Medullary thyroid carcinoma (MTC) is a rare tumor arising from C cells of the thyroid gland and belonging to the endocrine tumors. 18F-DOPA PET, based on tha capacity of endocrine tumor cells to take-up, decarboxylate and store amino-acids, such 3-4-dihydroxyphenylalanine(DOPA), is used for imaging endocrine tumors. The aim of the study was to evaluate the contribution of 18F-DOPA whole-body PET for the detection of recurrences in patients with proven recurrent MTC without evidence of recurrence or metastases on several imaging modalities.

In patients MTC and persistently elevated calcitonin levels, the challenge is finding the site of residual disease. Since the only satisfying treatment is surgery, the early detection and precise location is important. Tumor localization techniques usually performed, including ultrasonography of the neck and liver, chest and abdomen, bone scintigraphy, isotopic scanning and even PET with FDG are poorly sensitive. The use of 18F-DOPA may be more sensitive and specific engineering for localization metastatic disease. The study include 100 patient with persistent MTC demonstrated by elevated tumor markers (calcitonin and CEA) and no evidence of recurrence on morphological imaging procedures. 18F-DOPA whole-body PET is performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA, the patient fasted for 6 hours prior the start of the examination.

All 18F-DOPA PET are evaluated independently by two experienced nuclear medicine physicians and any tracer accumulation exceeding the normal uptake tissue is rated as pathologic finding. The sensibility and efficiency of 18F-DOPA PET will be analysed and Malignant tissue confirmed by histology after surgery or biopsy or by follow-up for one year.

Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer

Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer.

Assistance Publique - Hôpitaux de Paris

Zakia.IDIR

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer	NCT00647140	Thyroid Neoplas... Thyroid Carcino... Medullary Carci...	18F-L-DOPA PET	18 Years -	Assistance Publique - Hôpitaux de Paris
Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer	NCT00647140	Thyroid Neoplas... Thyroid Carcino... Medullary Carci...	18F-L-DOPA PET	18 Years -	Assistance Publique - Hôpitaux de Paris

Spots Global Cancer Trial Database for osseous radionuclide imaging